533 related articles for article (PubMed ID: 29025766)
21. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
22. Intercellular adhesion molecule-1 (ICAM-1) immunoreactivity in well-differentiated thyroid papillary carcinomas.
Tanda F; Cossu A; Bosincu L; Manca A; Ibba M; Massarelli G
Mod Pathol; 1996 Jan; 9(1):53-6. PubMed ID: 8821957
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.
Mehta A; Zhang L; Boufraqech M; Liu-Chittenden Y; Zhang Y; Patel D; Davis S; Rosenberg A; Ylaya K; Aufforth R; Li Z; Shen M; Kebebew E
Clin Cancer Res; 2015 Sep; 21(18):4123-32. PubMed ID: 25944801
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
Zhang K; Yu M; Hao F; Dong A; Chen D
Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
[TBL] [Abstract][Full Text] [Related]
25. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
26. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.
Oweida A; Phan A; Vancourt B; Robin T; Hararah MK; Bhatia S; Milner D; Lennon S; Pike L; Raben D; Haugen B; Pozdeyev N; Schweppe R; Karam SD
Thyroid; 2018 Jun; 28(6):739-747. PubMed ID: 29774792
[TBL] [Abstract][Full Text] [Related]
28. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
29. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
30. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.
Gómez Sáez JM; Jiménez-Fonseca P; Santamaría Sandi J; Capdevila Castillón J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Riesco Eizaguirre G; Grande Pulido E; Galofré Ferrater JC
Endocrinol Nutr; 2015 Mar; 62(3):e15-22. PubMed ID: 25583658
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
32. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.
Liu Y; Gunda V; Zhu X; Xu X; Wu J; Askhatova D; Farokhzad OC; Parangi S; Shi J
Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7750-5. PubMed ID: 27342857
[TBL] [Abstract][Full Text] [Related]
33. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
34. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case.
Juhlin CC; Höög A
Int J Surg Pathol; 2019 Sep; 27(6):658-663. PubMed ID: 30931661
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.
Yoshida A; Sugino K; Sugitani I; Miyauchi A
World J Surg; 2014 Sep; 38(9):2311-6. PubMed ID: 24687351
[TBL] [Abstract][Full Text] [Related]
36. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
38. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
39. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
40. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.
Li H; Zhou X; Wang G; Hua D; Li S; Xu T; Dong M; Cui X; Yang X; Wu Y; Cai M; Liao X; Zhang T; Yang Z; Du Y; Li X
J Clin Endocrinol Metab; 2022 Mar; 107(4):1110-1126. PubMed ID: 34751400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]